BRIEF-Gensight Biologics Reaches Deal With ANSM For Opening Of Lumevoq Early Access Program In France

-0.51%

-1.07%

-1.69%

Dow Jones Industrial Average

DJI

48458.05

-0.51%

S&P 500 index

SPX

6827.41

-1.07%

NASDAQ

IXIC

23195.17

-1.69%

June 12 (Reuters) - Gensight Biologics SA SIGHT.PA:

GENSIGHT BIOLOGICS REACHES AGREEMENT WITH ANSM FOR OPENING OF LUMEVOQ® NAMED EARLY ACCESS PROGRAM (AAC) IN FRANCE
GENSIGHT BIOLOGICS SA - TARGETS Q3 2025 FOR FINALIZING DOSE-RANGING STUDY PROTOCOL
GENSIGHT BIOLOGICS SA - AAC PROGRAM TARGETED TO OPEN IN Q4 2025

Source text: ID:nBw32Cm9Qa

Further company coverage: SIGHT.PA

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.